Eli Lilly and Company (NYSE:LLY) issued an update on its FY17 earnings guidance on Tuesday morning. The company provided EPS guidance of $4.10-4.20 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.12. The company issued revenue guidance of $22.0-22.5 billion, compared to the consensus revenue estimate of $22.15 billion.
Shares of Eli Lilly and Company (NYSE:LLY) opened at 81.15 on Friday. Eli Lilly and Company has a 1-year low of $64.18 and a 1-year high of $86.72. The firm has a market capitalization of $85.61 billion, a price-to-earnings ratio of 35.11 and a beta of 0.34. The company’s 50-day moving average is $82.91 and its 200 day moving average is $81.72.
Eli Lilly and (NYSE:LLY) last issued its earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.05 by $0.06. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The company had revenue of $5.82 billion for the quarter, compared to analyst estimates of $5.60 billion. During the same quarter last year, the firm earned $0.86 EPS. The company’s revenue for the quarter was up 7.8% on a year-over-year basis. On average, analysts expect that Eli Lilly and Company will post $4.16 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Tuesday, August 15th will be paid a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.56%. The ex-dividend date is Friday, August 11th. Eli Lilly and’s payout ratio is 90.04%.
LLY has been the topic of several recent analyst reports. UBS AG lowered shares of Eli Lilly and to a hold rating and set a $85.00 price objective on the stock. in a research note on Wednesday, July 26th. Piper Jaffray Companies reissued a buy rating and set a $100.00 price objective on shares of Eli Lilly and in a research note on Monday, April 17th. Argus lowered shares of Eli Lilly and from a buy rating to a hold rating and lifted their price objective for the stock from $64.18 to $81.00 in a research note on Thursday, April 27th. They noted that the move was a valuation call. Jefferies Group LLC reissued a buy rating and set a $93.00 price objective on shares of Eli Lilly and in a research note on Thursday, June 22nd. Finally, Sanford C. Bernstein reissued an outperform rating and set a $88.00 price objective on shares of Eli Lilly and in a research note on Sunday, May 21st. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have assigned a buy rating to the stock. Eli Lilly and has an average rating of Hold and an average price target of $88.27.
In related news, VP Michael J. Harrington sold 22,833 shares of the business’s stock in a transaction on Friday, June 9th. The shares were sold at an average price of $79.97, for a total transaction of $1,825,955.01. Following the transaction, the vice president now directly owns 62,056 shares in the company, valued at $4,962,618.32. The sale was disclosed in a filing with the SEC, which is available through this link. Also, major shareholder Lilly Endowment Inc sold 215,000 shares of the business’s stock in a transaction on Tuesday, June 20th. The stock was sold at an average price of $83.05, for a total transaction of $17,855,750.00. Following the transaction, the insider now owns 124,475,804 shares in the company, valued at $10,337,715,522.20. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 669,733 shares of company stock worth $55,845,287. 0.20% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: This story was published by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright law. The original version of this story can be read at https://www.com-unik.info/2017/08/12/eli-lilly-and-company-lly-releases-fy17-earnings-guidance-updated-updated.html.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
What are top analysts saying about Eli Lilly and Company? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Eli Lilly and Company and related companies.